Suvorexant: A promising, novel treatment for insomnia

Joyce K. Lee-Iannotti, James M. Parish

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others.

Original languageEnglish (US)
Pages (from-to)491-495
Number of pages5
JournalNeuropsychiatric Disease and Treatment
StatePublished - Feb 25 2016


  • Benzodiazepan receptor antagonist
  • CYP3A4
  • Insomnia
  • MK-4305
  • Orexin-receptor antagonist

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Suvorexant: A promising, novel treatment for insomnia'. Together they form a unique fingerprint.

Cite this